Abstract
Biomarker research provides the opportunity to risk stratify patients based on identified prognostic and predictive markers. The need for such biomarkers is evident to improve response and survival outcomes in head and neck cancer through more rational patient selection for intensive curative regimens as well as palliative treatments. Advances in our understanding of genomics, epigenetics, and immunology of head and neck cancer are accelerating the discovery of new biomarkers. With the increasing availability of molecularly targeted therapeutics, it is very important to identify and validate biomarkers in the appropriate clinical setting to translate the advances into improved clinical outcome. This chapter focuses on human papillomavirus (HPV) status as a validated prognostic biomarker and discusses emerging prognostic and/or predictive biomarkers with potential for testing through prospective clinical trials. The availability of validated diagnostic assays and required multi-institutional trials for selected patients presents logistical challenges in biomarker research for head and neck cancer.
| Original language | English (US) |
|---|---|
| Title of host publication | Head and Neck Cancer: Multimodality Management, Second Edition |
| Publisher | Springer International Publishing |
| Pages | 149-162 |
| Number of pages | 14 |
| ISBN (Electronic) | 9783319276014 |
| ISBN (Print) | 9783319275994 |
| DOIs | |
| State | Published - Jan 1 2016 |
Keywords
- Head and neck cancer
- Molecular biomarkers
- Predictive and prognostic markers
- Therapeutic targets
ASJC Scopus subject areas
- Medicine(all)